logo
logo
HomeAbout UsPlatformInsights

Clinical Trial Insights

AllClinical TrialRegulatoryMerger & AcquisitionsBlogs
KALA BIO Completes Enrollment in CHASE Trial for KPI-012 in Persistent Corneal Epithelial DefectClinical Trial Updates

10 Jul 2025

KALA BIO Completes Enrollment in CHASE Trial for KPI-012 in Persistent Corneal Epithelial Defect

KALA BIO announced the completion of patient enrollment in the CHASE Phase 2b clinical trial evaluating KPI-012, a human mesenchymal stem cell secreto...

Silexion Therapeutics Announces Positive Preclinical Results for SIL204 in Lung CancerClinical Trial Updates

10 Jul 2025

Silexion Therapeutics Announces Positive Preclinical Results for SIL204 in Lung Cancer

Silexion Therapeutics announced positive preclinical data showing SIL204's significant efficacy in human lung cancer cell lines. SIL204, an RNA inter...

BriaCell's Phase 2 Trial Shows Promising Survival Rates in Metastatic Breast CancerClinical Trial Updates

09 Jul 2025

BriaCell's Phase 2 Trial Shows Promising Survival Rates in Metastatic Breast Cancer

BriaCell Therapeutics Corp. announced updated survival data from its Phase 2 clinical study of Bria-IMT in patients with metastatic breast cancer (MBC...

Cizzle Bio Submits NIH Grant for Lung Cancer Biomarker Blood TestClinical Trial Updates

09 Jul 2025

Cizzle Bio Submits NIH Grant for Lung Cancer Biomarker Blood Test

Cizzle Bio, a biotechnology company, submitted a grant application to the NIH for a two-year study validating its CIZ1B biomarker for early-stage lung...

MediView Launches Multicenter Study for XR90 Surgical Navigation System in Soft Tissue BiopsyClinical Trial Updates

09 Jul 2025

MediView Launches Multicenter Study for XR90 Surgical Navigation System in Soft Tissue Biopsy

MediView has initiated a multicenter clinical study to evaluate the XR90 Holographic Surgical Navigation system's effectiveness in percutaneous soft t...

Plus Therapeutics Announces Initial Patient Treatment in REYOBIQ™ Leptomeningeal Metastases Dose Optimization TrialClinical Trial Updates

09 Jul 2025

Plus Therapeutics Announces Initial Patient Treatment in REYOBIQ™ Leptomeningeal Metastases Dose Optimization Trial

Plus Therapeutics announced the treatment of the first patients in its ReSPECT-LM dose optimization trial for REYOBIQ™ (rhenium Re186 obisbemeda) in l...

Caris Assure® Blood-Based Assay Shows Promise for Multi-Cancer Early Detection and MonitoringClinical Trial Updates

08 Jul 2025

Caris Assure® Blood-Based Assay Shows Promise for Multi-Cancer Early Detection and Monitoring

Caris Life Sciences announced a study published in Scientific Reports demonstrating the accuracy and clinical utility of its Caris Assure® blood-based...

MapLight Therapeutics Initiates Phase 2 Trial for ML-007C-MA in SchizophreniaClinical Trial Updates

08 Jul 2025

MapLight Therapeutics Initiates Phase 2 Trial for ML-007C-MA in Schizophrenia

MapLight Therapeutics has begun a Phase 2 clinical trial (ZEPHYR) to assess the efficacy, safety, and tolerability of ML-007C-MA, a novel M1/M4 muscar...

Ascletis Initiates Phase IIa Trial of Oral GLP-1R Agonist ASC30 for ObesityClinical Trial Updates

03 Jul 2025

Ascletis Initiates Phase IIa Trial of Oral GLP-1R Agonist ASC30 for Obesity

Ascletis Pharma announced the first participants have been dosed in a Phase IIa clinical trial (NCT07002905) evaluating ASC30, a novel small molecule ...

Soleno Therapeutics Announces Presentations on VYKAT™ XR for Prader-Willi Syndrome at ENDO 2025Clinical Trial Updates

02 Jul 2025

Soleno Therapeutics Announces Presentations on VYKAT™ XR for Prader-Willi Syndrome at ENDO 2025

Soleno Therapeutics announced that two presentations featuring data on VYKAT™ XR (diazoxide choline) extended-release tablets for the treatment of hyp...

Clene Provides Regulatory Update on CNM-Au8 for ALS and MSClinical Trial Updates

01 Jul 2025

Clene Provides Regulatory Update on CNM-Au8 for ALS and MS

Clene, Inc. announced a positive Type C meeting with the FDA regarding its statistical analysis plan for CNM-Au8 in ALS patients. The FDA provided co...

OS Therapies Announces Positive Phase 2b Data for OST-HER2 in OsteosarcomaClinical Trial Updates

01 Jul 2025

OS Therapies Announces Positive Phase 2b Data for OST-HER2 in Osteosarcoma

OS Therapies announced positive one-year event-free survival (EFS), overall survival, and safety data from its Phase 2b trial of OST-HER2 in patients ...

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Pain TreatmentClinical Trial Updates

30 Jun 2025

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Pain Treatment

Artelo Biosciences announced positive results from its first-in-human Phase 1 study of ART26.12, a novel, orally administered FABP5 inhibitor for pers...

Klotho Neurosciences Advances Manufacturing of ALS Gene Therapy KLTO-202Clinical Trial Updates

30 Jun 2025

Klotho Neurosciences Advances Manufacturing of ALS Gene Therapy KLTO-202

Klotho Neurosciences announced it is progressing with manufacturing and process development for KLTO-202, a gene therapy targeting amyotrophic lateral...

MeCo Score: A Novel Biomarker for Predicting Response to Antifibrotic Therapy in Breast CancerClinical Trial Updates

30 Jun 2025

MeCo Score: A Novel Biomarker for Predicting Response to Antifibrotic Therapy in Breast Cancer

A multinational study published in the journal *Cancers* reveals that the MeCo Score, a novel biomarker, quantifies mechanical conditioning in breast ...

Moderna Announces Positive Phase 3 Results for Seasonal Influenza VaccineClinical Trial Updates

30 Jun 2025

Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine

Moderna announced positive Phase 3 results for its seasonal influenza vaccine candidate, mRNA-1010. The study demonstrated a 26.6% higher relative va...

Aldeyra Therapeutics Receives FDA Special Protocol Assessment for ADX-2191 in Primary Vitreoretinal LymphomaClinical Trial Updates

26 Jun 2025

Aldeyra Therapeutics Receives FDA Special Protocol Assessment for ADX-2191 in Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics announced that it received a Special Protocol Assessment Agreement from the FDA for ADX-2191, a novel formulation of methotrexate...

DBV Technologies Begins Phase 3 Safety Study for Viaskin Peanut Patch in Peanut-Allergic ToddlersClinical Trial Updates

26 Jun 2025

DBV Technologies Begins Phase 3 Safety Study for Viaskin Peanut Patch in Peanut-Allergic Toddlers

DBV Technologies announced the first subject has been screened in its COMFORT Toddlers study, a Phase 3 supplemental safety study evaluating the Viask...

Edgewise Therapeutics Announces Positive Sevasemten Results for Becker and Duchenne Muscular DystrophyClinical Trial Updates

26 Jun 2025

Edgewise Therapeutics Announces Positive Sevasemten Results for Becker and Duchenne Muscular Dystrophy

Edgewise Therapeutics reported positive results from its sevasemten program for Becker and Duchenne muscular dystrophies. In Becker MD, open-label da...

Alafair Biosciences Initiates Multi-Center Study on VersaWrap® for Achilles Tendon RepairClinical Trial Updates

25 Jun 2025

Alafair Biosciences Initiates Multi-Center Study on VersaWrap® for Achilles Tendon Repair

Alafair Biosciences announced the enrollment of the first patient in a multi-center study evaluating VersaWrap®, a bioresorbable tendon protector, for...

Enterra Medical Initiates NAVIGATE Study for Gastric Electrical Stimulation (GES) in Chronic NauseaClinical Trial Updates

25 Jun 2025

Enterra Medical Initiates NAVIGATE Study for Gastric Electrical Stimulation (GES) in Chronic Nausea

Enterra Medical has launched the NAVIGATE study to evaluate the safety and effectiveness of Gastric Electrical Stimulation (GES) for treating chronic ...

GeneDx's SeqFirst Study Shows Rapid Genomic Testing Significantly Improves Pediatric DiagnosisClinical Trial Updates

25 Jun 2025

GeneDx's SeqFirst Study Shows Rapid Genomic Testing Significantly Improves Pediatric Diagnosis

GeneDx announced data from the SeqFirst study, conducted in partnership with Seattle Children's, demonstrating the effectiveness of rapid exome sequen...

ONCare Alliance and Exigent Research Launch Outpatient Bispecifics Cancer Treatment ProgramClinical Trial Updates

25 Jun 2025

ONCare Alliance and Exigent Research Launch Outpatient Bispecifics Cancer Treatment Program

ONCare Alliance and Exigent Research have launched a groundbreaking outpatient bispecific antibody program for cancer treatment. This program, develo...

Oncotelic Therapeutics Announces Publication Showing TGFB2 Methylation as Positive Prognostic Marker in Pancreatic CancerClinical Trial Updates

25 Jun 2025

Oncotelic Therapeutics Announces Publication Showing TGFB2 Methylation as Positive Prognostic Marker in Pancreatic Cancer

Oncotelic Therapeutics announced the publication of a study in the *International Journal of Molecular Sciences* showing that TGFB2 gene methylation i...

Vial Initiates Phase 1 Trial of Subcutaneous Half-Life Extended Anti-TL1A Antibody for IBDClinical Trial Updates

25 Jun 2025

Vial Initiates Phase 1 Trial of Subcutaneous Half-Life Extended Anti-TL1A Antibody for IBD

Vial, a clinical-stage biotechnology company, announced the first-in-human dosing of its novel, subcutaneous, half-life extended monoclonal antibody t...

Immunic Reports Positive Long-Term Data for Vidofludimus Calcium in MSClinical Trial Updates

24 Jun 2025

Immunic Reports Positive Long-Term Data for Vidofludimus Calcium in MS

Immunic, Inc. announced positive long-term open-label extension (OLE) data from its Phase 2 EMPhASIS trial of vidofludimus calcium (IMU-838) in relaps...

Compass Pathways' COMP360 Psilocybin Shows Positive Phase 3 Results for Treatment-Resistant DepressionClinical Trial Updates

23 Jun 2025

Compass Pathways' COMP360 Psilocybin Shows Positive Phase 3 Results for Treatment-Resistant Depression

Compass Pathways announced positive top-line results from its Phase 3 COMP005 trial evaluating COMP360, a synthetic psilocybin formulation, for treatm...

Novo Nordisk Advances Amycretin, an Obesity Medication, to Phase 3 Clinical DevelopmentClinical Trial Updates

23 Jun 2025

Novo Nordisk Advances Amycretin, an Obesity Medication, to Phase 3 Clinical Development

Novo Nordisk announced positive results from two early-phase clinical trials of amycretin, a novel investigational obesity treatment, published in The...

Qlaris Bio to Present New Data on QLS-111 for Glaucoma at World Glaucoma CongressClinical Trial Updates

23 Jun 2025

Qlaris Bio to Present New Data on QLS-111 for Glaucoma at World Glaucoma Congress

Qlaris Bio announced that new clinical and preclinical data on its lead investigational compound, QLS-111, will be presented at the 2025 World Glaucom...

Soleno Therapeutics Announces Presentations on Diazoxide Choline for Prader-Willi Syndrome at International ConferenceClinical Trial Updates

23 Jun 2025

Soleno Therapeutics Announces Presentations on Diazoxide Choline for Prader-Willi Syndrome at International Conference

Soleno Therapeutics announced multiple presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference. The presentations wi...

Poxel SA Highlights Imeglimin's Potential at ADA 2025Clinical Trial Updates

20 Jun 2025

Poxel SA Highlights Imeglimin's Potential at ADA 2025

Poxel SA announced that five presentations on the therapeutic potential of Imeglimin (TWYMEEG®), a first-in-class treatment for type 2 diabetes, will ...

UCB Presents Thymidine Kinase 2 Deficiency (TK2d) Research at UMDF 2025 ConferenceClinical Trial Updates

20 Jun 2025

UCB Presents Thymidine Kinase 2 Deficiency (TK2d) Research at UMDF 2025 Conference

UCB presented new research on thymidine kinase 2 deficiency (TK2d) at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference. The present...

Indivior Presents Data on SUBLOCADE for Opioid Use Disorder in High Fentanyl UsersClinical Trial Updates

19 Jun 2025

Indivior Presents Data on SUBLOCADE for Opioid Use Disorder in High Fentanyl Users

Indivior presented new data at the College on Problems of Drug Dependence (CPDD) meeting, showing that a higher dose (300mg) of SUBLOCADE (buprenorphi...

Telomir Pharmaceuticals' Telomir-1 Shows Promise in Preventing Cellular Aging in ProgeriaClinical Trial Updates

18 Jun 2025

Telomir Pharmaceuticals' Telomir-1 Shows Promise in Preventing Cellular Aging in Progeria

Telomir Pharmaceuticals announced preclinical data showing its lead candidate, Telomir-1, prevented cellular aging in human progeria cell lines. Telo...

Tevogen Updates Development of AI-Powered EBV-Specific T Cell TherapyClinical Trial Updates

18 Jun 2025

Tevogen Updates Development of AI-Powered EBV-Specific T Cell Therapy

Tevogen Bio Holdings Inc. announced an update on its development of a cytotoxic T lymphocyte (CTL) therapy targeting Epstein-Barr virus (EBV)-associat...

AbbVie's VERONA Trial for Higher-Risk Myelodysplastic Syndromes Misses Primary EndpointClinical Trial Updates

17 Jun 2025

AbbVie's VERONA Trial for Higher-Risk Myelodysplastic Syndromes Misses Primary Endpoint

AbbVie announced that the Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine for newly diagnosed higher-risk myelodysplastic s...

Breathe BioMedical Expands Multi-Center Breast Cancer Breath Test TrialClinical Trial Updates

17 Jun 2025

Breathe BioMedical Expands Multi-Center Breast Cancer Breath Test Trial

Breathe BioMedical announced the launch of the second site in its multi-center observational study evaluating a breath test for early breast cancer de...

Hengrui and Kailera Present Clinical Data for HRS9531 and HRS-7535 at ADA 2025Clinical Trial Updates

17 Jun 2025

Hengrui and Kailera Present Clinical Data for HRS9531 and HRS-7535 at ADA 2025

Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics announced the presentation of six abstracts at the American Diabetes Association's 85th Scien...

Lyell Immunopharma Announces Positive Clinical Data for LYL314 in Large B-cell LymphomaClinical Trial Updates

17 Jun 2025

Lyell Immunopharma Announces Positive Clinical Data for LYL314 in Large B-cell Lymphoma

Lyell Immunopharma announced positive Phase 1/2 clinical trial data for LYL314, a dual-targeting CD19/CD20 CAR T-cell therapy, in patients with relaps...

Ocugen Announces FDA Clearance for Phase 2/3 Trial of OCU410ST for Stargardt DiseaseClinical Trial Updates

17 Jun 2025

Ocugen Announces FDA Clearance for Phase 2/3 Trial of OCU410ST for Stargardt Disease

Ocugen, Inc. announced that the U.S. FDA has cleared an Investigational New Drug (IND) amendment to initiate a Phase 2/3 pivotal confirmatory clinical...

← PrevPage 7 of 10Next →